Answers are grounded in this paper and cite their sources.
Chronic kidney disease–mineral and bone disorder (CKD-MBD) comprises several bone-turnover phenotypes and carries a high risk of fracture. In this narrative review, we examine how reactive oxygen species (ROS) regulate osteoclast differentiation driven by receptor activator of nuclear factor-κB ligand (RANKL), and how uremic solutes, secondary hyperparathyroidism, disturbances of phosphate, fibroblast growth factor 23 (FGF23), and Klotho, inflammation, and weakened antioxidant defenses may alter this response in CKD. We also outline the metabolic programme of the osteoclast lineage, including mitochondrial biogenesis, glycolytic adaptation, NADPH and glutamine supply and hypoxia signalling, and relate it to ROS generation and antioxidant defence. Because bone is remodelled by osteoclasts, osteoblasts and osteocytes together, we summarise redox effects in these cells and consider how oxidative stress may contribute to low-turnover as well as high-turnover disease. Gut dysbiosis may contribute through microbial toxin precursors, intestinal barrier dysfunction, and reduced production of short-chain fatty acids, although the evidence for these gut–bone links is mainly mechanistic and hypothesis-generating. Experimental work implicates NF-κB, MAPK, AKT/FOXO, and Keap1/Nrf2 signaling, although the direction and clinical weight of gut-derived and redox effects probably differ between high- and low-turnover disease. Direct evidence from human CKD bone is scarce, and no antioxidant or microbiota-targeted intervention has yet been shown to prevent fractures. Oxidative-stress biomarkers are not standardised in CKD and have not been validated, alone or with bone-turnover markers, for selecting patients for redox-targeted treatment. For now, management should rest on fracture risk, serial CKD-MBD biochemistry, assessment of bone turnover where indicated, and the safety of antiresorptive drugs in advanced CKD. Prospective studies that measure microbial metabolites, redox markers, bone turnover and structure, and fractures together are needed to establish whether these pathways are worth targeting.
No takes yet. Share an insight, caveat, or question.
Kuo‐Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: